57 results about "Kidney transplant" patented technology

The present invention relates to HLA-A*02-restricted cellular epitopes within the VP1 polypeptide of a human polyomavirus, BK virus, which is associated with polyomavirus-associated nephropathy in kidney transplant patients. Preferred peptides correspond to amino acids residues 107-116, 108-116 and 44-52 of BKV VP1, and are processed in vivo in natural infection with BKV. Effector T cell populations stimulated by the peptides represent functional CTLs as assessed by cytotoxicity and cytokine production, and are reactive against cells presenting both the BKV peptides above and the JC virus homolog sequences.

The invention discloses an intraoperative low temperature kidney protective bag and a using method thereof. The intraoperative low temperature kidney protective bag comprises a protective bag body, acool storage interlayer, inner layer folds, a cold storage infusion port, a kidney placing inlet and a kidney gate opening. The cool storage interlayer is arranged in the protective bag body; the inner wall of the protective bag body is provided with the inner layer folds, and the inner layer folds enclose to form an inner cavity; the inner cavity is filled with kidney protection liquid; the upperpart of the protective bag body is provided with the kidney placing inlet, a first elastic rubber ring is arranged at the kidney placing inlet, the lower part of the protective bag body is provided with the kidney gate opening, and a second elastic rubber ring is arranged at the kidney gate opening; the first elastic rubber ring and the second elastic rubber are both provided with elastic retractable ropes. The intraoperative low temperature kidney protective bag can ensure cryopreservation effect of a kidney during a kidney transplant operation process, and effectively improve preservation quality of the kidney. The intraoperative low temperature kidney protective bag is an easy-to-operate special refrigerated storage bag for transplanted kidney, and can be specially used in a kidney transplant operation.

Methods for the treatment of acute renal failure, multi-organ failure, early dysfunction of kidney transplant, chronic renal failure, organ dysfunction, and wound healing are provided. The methods include delivering a therapeutic amount of hematopoietic stem cells, non-hematopoietic, mesenchymal stem cells, hemangioblasts, and pre-differentiated cells to a patient in need thereof.

The invention provides a kidney surgery model capable of simulating blood circulating and urine generating functions. Compared with existing kidney simulation devices which are appearance models onlyand have the problems of being simple in structure, unitary in function, low in simulation degree and unsupportive of teaching demonstration and surgery operation, the kidney surgery model can be usedfor preclinical teaching and scientific research. The model simulating human kidney organs and parts thereof is made according to a proportion of 1:1, thereby being high in simulation level, and a relation between kidney blood circulation and urine generation can be simulated through a pulse pump, a pressure control part and a valve; parts of the model are assembled and spliced, so that the modelcan be used for clinical surgical operation and teaching demonstration, medical staff can simulate related process operations of a kidney transplanting surgery, and understanding on kidney organ andsurgical success rate of the medical staff are improved.

A method and composition for enhancing the development of metanephric tissue upon transplantation into an allogenic or xenogenic host are disclosed. Metanephric tissue is removed from an embryonic donor and is contacted with a composition comprising one or more growth factors for metanephric development. The composition can be administered to the metanephric tissue in vitro prior to implantation of the donor tissue in the transplant recipient, or can be administered in vivo either during or subsequent to the transplantation procedure.

The present invention relates generally to methods of for the prevention and treatment for renal disease. In particular, the invention relates to methods of prevention and treatment of mammals, including humans, which are at risk of developing renal failure. This is generally in the field of treatment or prevention of acute renal failure by administration of the anti-apoptotic molecule survivin. The invention also includes the treatment of kidney transplants (renal allografts) to prolong survival of the graft during cold ischemia and immediately after transplantation.

The invention provides the use of a glucocorticoid having a first pass metabolism in the liver of at least 90 % as active substance, for the manufacturing of a medicament for oral or rectal administration in the treatment of glomerulonephritis by releasing the active substance in the intestine. The invention also provides a method for treatment of glomerulonephritis in a native kidney or a kidney transplant with the glucocorticoid as defined above. The invention also comprises a composition comprising the active substance and a pharmaceutically acceptable carrier, adjuvant or diluent designed for oral or rectal administration.

The invention discloses an isolated kidney perfusion system, and relates to the technical field of kidney transplantation. According to the invention, a liquid conveying pipeline is used as a main body; a liquid inlet pipe, a liquid dripping bucket, a fluid speed regulation roller and an outflow assembly are sequentially arranged on the conveying pipeline in series; and through arrangement of theabove-mentioned structures, the isolated kidney perfusion system provided by the invention can make up the defect that a perfusion device used in the kidney transplantation process in the prior art isgenerally a self-made simple device and is inconvenient when a plurality of blood vessels are encountered or the blood vessels are thin. During kidney perfusion, a medicine can be injected through above-mentioned devices; a flow speed can be adjusted through a pulley; a pressure can be generated during liquid conversion and extrusion through a soft ball to facilitate perfusion; a proper siliconetube can be selected for perfusion according to the thickness and number of kidney arteries; thus, the isolated kidney perfusion system provided by the invention has the advantages of simple structure, widely-available materials, convenient operation, low price, practicality, sufficient perfusion, scientific and reasonable structure and safe and convenient use.

The invention discloses a storage device for kidney transplantation specimens, which relates to the field of medical instruments and comprises a fixedly connected upper box and a lower box. The upper end of the upper box is provided with a movable box door, and the upper box is provided with a The specimen storage mechanism, the lower box is provided with a drive mechanism, the drive mechanism can drive the specimen storage mechanism to rise or fall; it also includes a cold air system, a temperature sensor and a main controller arranged on the upper box, the cold air The system, drive mechanism and temperature sensor are all electrically connected to the main controller; this design is convenient for use and safe for storage.

Methods for the treatment of acute renal failure, multi-organ failure, early dysfunction of kidney transplant, chronic renal failure, organ dysfunction, and wound healing are provided. The methods include delivering a therapeutic amount of hematopoietic stem cells, non-hematopoietic, mesenchymal stem cells, hemangioblasts, and pre-differentiated cells to a patient in need thereof.

The present invention relates to HLA-A*02-restricted cellular epitopes within the VP1 polypeptide of a human polyomavirus, BK virus, which is associated with polyomavirus-associated nephropathy in kidney transplant patients. Preferred peptides correspond to amino acids residues 107-116, 108-116 and 44-52 of BKV VP1, and are processed in vivo in natural infection with BKV. Effector T cell populations stimulated by the peptides represent functional CTLs as assessed by cytotoxicity and cytokine production, and are reactive against cells presenting both the BKV peptides above and the JC virus homolog sequences.

The present invention relates to a medicine for treating chronic renal failure. The chronic renal failure is the final result of various kidney diseases, but without effective western medicine in clinic yet, and dialysis therapy and renal transplantation price are expensive and not suitable for early and middle patients. The medicine whole formula of the present invention both activates and tonifies, consideration to right and evil, nourishing and releasing integrated, leading nourishing not stagnating evil, releasing not injuring right, can not only delay chronic renal failure course, but also improve or eliminate clinical symptoms, having good curative effect, lower cost characteristic. The present invention concretely is with radix astragali, poria, hedyotis diffusa, serissa foetida, pyrola calliantha, ligusticum chuanxiong, morinda officinalis how, centella asiatica, prepared rhubarb and etc. traditional Chinese medicine to prepare into compound preparation. The present invention also relates to the medicine preparation method. As pharmacological experiment shows the present invention can obviously decrease adenine causing chronic renal failure rat and nephrectomy causing chronic renal failure rat kidney function Crea and BUN value, the present invention can also obviously increase water load rat urinary volume.